全文获取类型
收费全文 | 3122篇 |
免费 | 276篇 |
国内免费 | 196篇 |
专业分类
耳鼻咽喉 | 51篇 |
儿科学 | 43篇 |
妇产科学 | 25篇 |
基础医学 | 410篇 |
口腔科学 | 53篇 |
临床医学 | 384篇 |
内科学 | 486篇 |
皮肤病学 | 58篇 |
神经病学 | 252篇 |
特种医学 | 87篇 |
外国民族医学 | 1篇 |
外科学 | 318篇 |
综合类 | 427篇 |
一般理论 | 2篇 |
预防医学 | 205篇 |
眼科学 | 69篇 |
药学 | 295篇 |
5篇 | |
中国医学 | 106篇 |
肿瘤学 | 317篇 |
出版年
2024年 | 11篇 |
2023年 | 45篇 |
2022年 | 101篇 |
2021年 | 118篇 |
2020年 | 91篇 |
2019年 | 95篇 |
2018年 | 118篇 |
2017年 | 76篇 |
2016年 | 85篇 |
2015年 | 146篇 |
2014年 | 143篇 |
2013年 | 141篇 |
2012年 | 179篇 |
2011年 | 244篇 |
2010年 | 151篇 |
2009年 | 115篇 |
2008年 | 140篇 |
2007年 | 166篇 |
2006年 | 173篇 |
2005年 | 174篇 |
2004年 | 134篇 |
2003年 | 124篇 |
2002年 | 108篇 |
2001年 | 84篇 |
2000年 | 74篇 |
1999年 | 102篇 |
1998年 | 48篇 |
1997年 | 44篇 |
1996年 | 37篇 |
1995年 | 24篇 |
1994年 | 20篇 |
1993年 | 19篇 |
1992年 | 36篇 |
1991年 | 33篇 |
1990年 | 31篇 |
1989年 | 17篇 |
1988年 | 18篇 |
1987年 | 16篇 |
1986年 | 11篇 |
1985年 | 6篇 |
1984年 | 11篇 |
1983年 | 11篇 |
1982年 | 6篇 |
1981年 | 5篇 |
1979年 | 7篇 |
1978年 | 6篇 |
1975年 | 5篇 |
1973年 | 9篇 |
1968年 | 4篇 |
1966年 | 4篇 |
排序方式: 共有3594条查询结果,搜索用时 31 毫秒
101.
102.
103.
Pullarkat VA Bueso-Ramos C Lai R Kroft S Wilson CS Pullarkat ST Bu X Thein M Lee M Brynes RK 《American journal of hematology》2003,73(1):12-17
The majority of patients with systemic mastocytosis with associated clonal, hematological non-mast cell lineage disease (SM-AHNMD) have a myeloid stem cell malignancy including myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative disorders, acute myeloid leukemia (AML), or chronic myeloproliferative disease. The clinicopathologic features of SM-AHNMD have not been fully characterized. We describe seven cases of this entity: 3 with MDS, 3 with AML, and 1 with chronic myelomonocytic leukemia. In the majority of cases, SM was diagnosed concurrently with the myeloid malignancy and aberrant mast cell morphology was observed. The commonly described c-kit enzymatic site mutation Asp816Val was detected only in 2 cases, while 3 patients carried the Asp816His mutation. Among the 3 cases with AML, 2 patients carried the translocation t(8;21). On the basis of our results and other reported cases, there appears to be a specific association between SM and AML with t(8;21). Concurrent occurrence of SM may define a subset of patients with de novo AML and other myeloid malignancies who have an adverse prognosis. As clinically effective tyrosine kinase inhibitors that inhibit enzymatic-type c-kit mutations are being developed, detection of mast cell proliferation associated with myeloid malignancy may have important therapeutic implications. 相似文献
104.
105.
Sang Kyung Jung Kyung-Ah Kim So Young Ha Hyun Kyo Lee Young Doo Kim Bu Hyun Lee Woo Hyun Paik Jong Wook Kim Won Ki Bae Nam-Hoon Kim June Sung Lee Yoon Jung Jwa 《Clinical and molecular hepatology》2015,21(1):41-48
Background/Aims
This study investigated the antiviral effects of tenofovir disoproxil fumarate (TDF) monotherapy in nucleos(t)ide analogue (NA)-naive and NA-experienced chronic hepatitis B (CHB) patients.Methods
CHB patients treated with TDF monotherapy (300 mg/day) for ≥12 weeks between December 2012 and July 2014 at a single center were retrospectively enrolled. Clinical, biochemical, and virological parameters were assessed every 12 weeks.Results
In total, 136 patients (median age 49 years, 96 males, 94 HBeAg positive, and 51 with liver cirrhosis) were included. Sixty-two patients were nucleos(t)ide (NA)-naïve, and 74 patients had prior NA therapy (NA-exp group), and 31 patients in the NA-exp group had lamivudine (LAM)-resistance (LAM-R group). The baseline serum hepatitis B virus (HBV) DNA level was 4.9±2.3 log IU/mL (mean±SD), and was higher in the NA-naïve group than in the NA-exp and LAM-R groups (5.9±2.0 log IU/mL vs 3.9±2.0 log IU/mL vs 4.2±1.7 log IU/mL, P<0.01). The complete virological response (CVR) rate at week 48 in the NA-naïve group (71.4%) did not differ significantly from those in the NA-exp (71.3%) and LAM-R (66.1%) groups. In multivariate analysis, baseline serum HBV DNA was the only predictive factor for a CVR at week 48 (hazard ratio, 0.809; 95% confidence interval, 0.729-0.898), while the CVR rate did not differ with the NA experience.Conclusions
TDF monotherapy was effective for CHB treatment irrespective of prior NA treatment or LAM resistance. Baseline serum HBV DNA was the independent predictive factor for a CVR. 相似文献106.
107.
108.
目的研究c-JNK信号通路在糖尿病(DM)大鼠左室心肌细胞电压门控钾通道(Kv)重构中的作用和内在调控机制。方法将50只健康SD大鼠随机分为DM组[n=25,采用链尿佐菌素(STZ)诱导成模]和对照组(sham)(n=25)。应用全细胞膜片钳方法记录DM组与sham组大鼠心室肌瞬时外向钾电流(Ito);使用非放射性JNK激酶分析kit进行c-Jun活性测定。应用JNK抑制剂SP600125(10M)对DM大鼠心肌细胞进行体外孵育,观察孵育前后心肌细胞Ito的变化。用硫氧还蛋白还原酶(TrxR)抑制剂金诺芬(AF)对经JNK抑制剂SP600125孵育的大鼠心肌细胞进行处理,观察处理前后心肌细胞Ito的变化。应用抗Kv4.2抗体对Kv4.2的含量进行检测,检测结果使用UVP生物成像系统进行分析。结果DM组心肌JNK活性显著升高超过1倍,而Ito显著降低[Sham组:(31.2±3.4)pA/pF,n=16;DM组:(15.4±3.1)pA/pF,n=17;P<0.05]。DM大鼠心室肌细胞经JNK抑制剂SP600125(10 M)处理4 h后,Ito电流密度可恢复至Sham组水平[DM+SP600125组:(31.9±3.8)pA/pF,n=18;Sham组:(31.2±3.4)pA/pF,n=16;P<0.05];且sham组经SP600125处理后的最大Ito电流强度[(29.8±3.4)pA/pF,n=9]和未经处理的sham组无统计学差异。DM心肌经膜渗透性蛋白抑制剂JNKI-1(10 M)处理后,Ito密度也有显著增加,而sham组经相同处理后无改变。TrxR抑制剂AF显著抑制了SP600125对DM大鼠心肌Ito电流的增大作用[DM+AF+SP600125:(15.5±3.2)pA/pF,n=17],而AF对sham组Ito无明显影响。JNK抑制剂SP600125治疗后DM大鼠心肌的Kv4.2蛋白表达量显著增大,尽管未完全恢复到sham组心肌水平,但与先前在DM大鼠心肌所观察到的Ito电流改变一致。而JNK抑制并没有明显改变sham组心肌的Kv4.2蛋白表达量。结论DM大鼠心肌钾通道重构是氧化还原敏感的,可能通过持续性激活c-JNK信号通路促进Ito重构。在DM心肌中,JNK活性显著增高,Kv通道的电流密度降低;抑制JNK信号通路后可显著改善Kv通道重构,这一过程可能被硫氧还原蛋白系统所调控。 相似文献
109.
Nodal promotes the generation of M2‐like macrophages and downregulates the expression of IL‐12
下载免费PDF全文
![点击此处可从《European journal of immunology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Xian‐Feng Wang Hong‐Sheng Wang Fan Zhang Qiang Guo Hao Wang Ke‐Fang Wang Ge Zhang Xian‐zhang Bu Shao‐Hui Cai Jun Du 《European journal of immunology》2014,44(1):173-183
Nodal, a member of the TGF‐β superfamily, is an embryonic morphogen that is upregulated in different types of tumors. Nodal increases the tumorigenesis by inducing angiogenesis and promoting metastasis. Importantly, Nodal inhibition suppresses the growth and invasion of tumor. Since tumor‐associated macrophages (TAMs) are the major infiltrating leukocytes in most cancers, we investigated whether Nodal is involved in the differentiation of TAMs. Our results revealed that Nodal inhibition in tumor microenvironment upregulated the production of IL‐12 in macrophages and reversed TAMs to classically activated macrophage phenotype. In contrast, treatment with recombinant Nodal (rNodal) decreased the expression of IL‐12 in murine macrophages. Furthermore, rNodal promoted macrophage polarization to an alternatively activated macrophage‐like/TAM phenotype and modulated its function. These results suggest that Nodal may play an important role in macrophage polarization and downregulation of IL‐12. The rescued antitumor function of TAMs via the inhibition of Nodal expression could be a new therapeutic strategy for cancer treatment. 相似文献
110.
Renfang Mao Wen Bu Chad J Creighton Pingju Zheng Sanjeev Vasudevan Lei An Jinshu Yang Yi‐Jue Zhao Huiyuan Zhang Xiao‐Nan Li Pulivarthi H Rao Eastwood Leung Yong‐Jie Lu Joe W Gray Rachel Schiff Susan G Hilsenbeck C Kent Osborne Jianhua Yang Hong Zhang 《The Journal of pathology》2014,232(1):75-86
Gene amplifications in the 17q chromosomal region are observed frequently in breast cancers. An integrative bioinformatics analysis of this region nominated the MAP3K3 gene as a potential therapeutic target in breast cancer. This gene encodes mitogen‐activated protein kinase kinase kinase 3 (MAP3K3/MEKK3), which has not yet been reported to be associated with cancer‐causing genetic aberrations. We found that MAP3K3 was amplified in approximately 8–20% of breast cancers. Knockdown of MAP3K3 expression significantly inhibited cell proliferation and colony formation in MAP3K3‐amplified breast cancer cell lines MCF‐7 and MDA‐MB‐361 but not in MAP3K3 non‐amplified breast cancer cells. Knockdown of MAP3K3 expression in MAP3K3‐amplified breast cancer cells sensitized breast cancer cells to apoptotic induction by TNFα and TRAIL, as well as doxorubicin, VP‐16 and fluorouracil, three commonly used chemotherapeutic drugs for treating breast cancer. In addition, ectopic expression of MAP3K3, in collaboration with Ras, induced colony formation in both primary mouse embryonic fibroblasts and immortalized human breast epithelial cells (MCF‐10A). Combined, these results suggest that MAP3K3 contributes to breast carcinogenesis and may endow resistance of breast cancer cells to cytotoxic chemotherapy. Therefore, MAP3K3 may be a valuable therapeutic target in patients with MAP3K3‐amplified breast cancers, and blocking MAP3K3 kinase activity with a small molecule inhibitor may sensitize MAP3K3‐amplified breast cancer cells to chemotherapy. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. 相似文献